These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 2203550)

  • 1. Development of vaccines against cholera and diarrhoea due to enterotoxigenic Escherichia coli: memorandum from a WHO meeting.
    Bull World Health Organ; 1990; 68(3):303-12. PubMed ID: 2203550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New vaccines against bacterial enteric infections.
    Holmgren J; Svennerholm AM
    Scand J Infect Dis Suppl; 1990; 70():149-56. PubMed ID: 2287897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study.
    Leyten EM; Soonawala D; Schultsz C; Herzog C; Ligthelm RJ; Wijnands S; Visser LG
    Vaccine; 2005 Oct; 23(43):5120-6. PubMed ID: 15982790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research priorities for diarrhoeal disease vaccines: memorandum from a WHO meeting.
    Bull World Health Organ; 1991; 69(6):667-76. PubMed ID: 1664785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of oral vaccines against cholera and enterotoxinogenic Escherichia coli diarrhea.
    Holmgren J; Svennerholm AM
    Scand J Infect Dis Suppl; 1990; 76():47-53. PubMed ID: 2102020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of mucosal immune response following oral administration of enterotoxigenic Escherichia coli fimbriae (CFA/I) entrapped in liposomes in conjunction with inactivated whole-cell Vibrio cholerae vaccine.
    Dima VF; Ionescu MD; Palade R; Balotescu C; Becheanu G; Dima SV
    Roum Arch Microbiol Immunol; 2001; 60(1):27-54. PubMed ID: 11850896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS.
    López-Gigosos R; García-Fortea P; Reina-Doña E; Plaza-Martín E
    Travel Med Infect Dis; 2007 Nov; 5(6):380-4. PubMed ID: 17983977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future vaccines against enteric pathogens.
    Levine MM; Edelman R
    Infect Dis Clin North Am; 1990 Mar; 4(1):105-21. PubMed ID: 2155260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral vaccines against cholera and enterotoxigenic Escherichia coli diarrhea.
    Svennerholm AM; Holmgren J
    Adv Exp Med Biol; 1995; 371B():1623-8. PubMed ID: 7502870
    [No Abstract]   [Full Text] [Related]  

  • 11. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
    Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
    Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of purified colonization factor antigens (CFA/I, CFA/II) of enterotoxigenic Escherichia coli to volunteers. Response to challenge with virulent enterotoxigenic Escherichia coli.
    Evans DG; Graham DY; Evans DJ
    Gastroenterology; 1984 Oct; 87(4):934-40. PubMed ID: 6381216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera.
    Jelinek T; Kollaritsch H
    Expert Rev Vaccines; 2008 Jul; 7(5):561-7. PubMed ID: 18564011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea.
    Lundkvist J; Steffen R; Jönsson B
    J Travel Med; 2009; 16(1):28-34. PubMed ID: 19192125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines against enterotoxigenic Escherichia coli.
    Svennerholm AM; Tobias J
    Expert Rev Vaccines; 2008 Aug; 7(6):795-804. PubMed ID: 18665777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic immunisation against traveller's diarrhoea caused by enterotoxin-forming strains of Escherichia coli and against cholera: does it make sense and for whom?
    Weinke T; Liebold I; Burchard GD; Frühwein N; Grobusch MP; Hatz C; Kollaritsch H; Nothdurft HD; Reisinger E; Rieke B; Schönfeld Ch; Steffen R; Stich A
    Travel Med Infect Dis; 2008 Nov; 6(6):362-7. PubMed ID: 18984481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal immunity and vaccine development: a WHO memorandum.
    Bull World Health Organ; 1979; 57(5):719-34. PubMed ID: 396051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on formulation of a combination heat killed immunogen from diarrheagenic Escherichia coli and Vibrio cholerae in RITARD model.
    Mukherjee P; Mondal V; Bhaumik U; Sinha R; Sarkar S; Mitra S; Howlader DR; Maiti S; Mukhopadhyay AK; Dutta S; Koley H
    Microbes Infect; 2019; 21(8-9):368-376. PubMed ID: 30853357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines for enterotoxigenic Escherichia coli: current status.
    Boedeker EC
    Curr Opin Gastroenterol; 2005 Jan; 21(1):15-9. PubMed ID: 15687879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea.
    Sánchez J; Holmgren J
    Curr Opin Immunol; 2005 Aug; 17(4):388-98. PubMed ID: 15963708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.